Related Experiment Video
Updated: May 27, 2025

Nano-Differential Scanning Fluorimetry for Screening in Fragment-based Lead Discovery
Published on: May 16, 2021
From part to whole: AI-driven progress in fragment-based drug discovery
Jinhyeok Yoo1, Wonkyeong Jang1, Woong-Hee Shin1
1Department of Biomedical Informatics, Korea University College of Medicine, Seoul, 02708, Republic of Korea.
Abstract:
Fragment-based drug discovery is a technique that finds potent binding fragments to the binding hotspots and makes them a hit compound. The combination of fragments allows us to explore the large chemical space. Thus, it becomes an effective methodology for identifying lead compounds. Three concepts have been introduced to make the fragments into the compound: growing, merging, and linking. Recently, growing and merging techniques using AI have significantly improved the accuracy and efficiency of molecular design. In this review, recent techniques such as VAE, reinforcement learning, and SE(3)-equivariant models will be discussed. These methods enable precise molecular structure exploration and optimization. Additionally, we address techniques utilizing diffusion models, language models, and deep evolutionary learning. We also introduce linker optimization methods using reinforcement learning and deep learning-based models. This progress of fragment-based drug discovery methods with AI opens the possibility of discovering the vast chemical space with high efficiency.
Related Concept Videos
Drug Discovery: Overview
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Targets for Drug Action: Overview
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...

